Truist analyst David MacDonald lowered the firm’s price target on Labcorp to $270 from $275 and keeps a Buy rating on the shares. The company’s base business trends remain strong with some Biopharma segment headwinds expected to alleviate throughout the year, though the firm’s price target cut reflects Labcorp’s guidance and updated 2024 reimbursement/PAMA assumptions, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LH: